DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical ...

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Indian drug major Sun Pharmaceutical Industries (BSE: 524715) has entered an agreement with Checkpoint Therapeutics (Nasdaq: ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...

Researchers have used machine learning to predict which patients with advanced bladder cancer are most likely to respond to ...

NIH clinical trials are a lifeline for cancer patients like Baltimore native Vanessa, who received a groundbreaking immunotherapy treatment at the Kimmel Cancer Center ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Q4 2024 Earnings Call Transcript March 6, 2025 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.22, ...